このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

進行性胆道癌患者におけるD07001-ソフトジェルカプセルとXeloda/TS-1の併用療法に関する研究

2026年11月2日 更新者:InnoPharmax Inc.

ゲムシタビンおよびシスプラチンベースの治療失敗後の進行性胆道がん患者におけるD07001-ソフトジェルカプセルとゼローダ/TS-1の併用療法に関する非盲検、多施設共同、第II/III相試験

The primary objective are:

To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1.

To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed by disease control rate (DCR).

調査の概要

詳細な説明

This open label, multicenter study will be conducted in 2 stages: a dose-finding stage (Phase IIa) and a dose-expansion stage (Phase IIb/III).

In phase IIa, eligible patients will be assigned to receive oral D07001-softgel on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle (9 doses per cycle) and Xeloda (or TS-1) twice daily on Day 1-14 of a 21-day cycle.

A modified 3+3 dose-finding design method will be applied to identify dose-limiting toxicities (DLTs) and establish the selected dose of D07001-softgel capsules plus Xeloda (or TS-1).

In phase IIb/III,the first 40 subjects (20 subjects per arm) will be randomly allocated in a 1:1 ratio in two arms. Arm A will receive active symptom control (ASC) with the selected dose from dose-finding stage of D07001-softgel capsules and Xeloda (or TS-1), in 21-day cycles. In arm B, subjects will receive ASC with mFOLFOX treatment. After the last subject of first 40 subjects will be completed the visit in the end of treatment, an adaptive interim analysis will be planned to re-estimate the required sample size based on the result of DCR if needed. The sponsor team will determine whether the study will be continued or stopped for futility.

If the study continues to proceed, the total subject number will be based on the decision from the results of interim study. The rest of subjects will be randomized to receive the combination of study drug or active-control drug with the same allocation in two arms. Both groups will continue the therapy until disease progression, withdrawn consent, or when another treatment discontinuation criterion is met.

研究の種類

介入

入学 (実際)

19

段階

  • フェーズ2
  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Kaohsiung City、台湾、807
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Taichung、台湾、404
        • China Medical University Hospital
      • Taipei、台湾
        • Taipei Veterans General Hospital
      • Taipei、台湾
        • National Taiwan University Cancer Center
      • Taipei、台湾
        • National Taiwan University Hospotal

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Male or female patients aged 18 years or older at screening (aged 20 years or older in Taiwan)

  2. Histopathological or cytologic diagnosis of unresectable metastatic or locally advanced BTC (cholangiocarcinoma, gallbladder cancer or ampullary carcinoma)

  3. Subject must have failed from first line gemcitabine and cisplatin-based chemotherapy

  4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-1

  5. Life expectancy is >12 weeks

  6. Adequate bone marrow function, demonstrated by:

    1. Absolute neutrophil count (ANC) ≥1,500 cell/mm3
    2. Platelet count ≥ 100,000 cells/mm3
    3. Hemoglobin ≥ 9 g/dL
  7. Adequate liver function, demonstrated by:

    1. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 x upper limit of normal (ULN), or ≤5.0 x ULN in the case of liver metastases
    2. Total bilirubin ≤1.5 x ULN
    3. Albumin ≥3.0 g/dL
    4. International normalized ratio (INR) <1.5
  8. Adequate renal function, demonstrated by:

    1. Serum creatinine ≤1.5 x ULN
    2. Creatinine clearance ≥ 50mL/min calculated by Cockcroft-Gault formula or eGFR ≥ 50mL/min/1.73m2 by 2021 CKD-EPI Creatinine Equation
  9. A negative serum pregnancy test at screening and is not breastfeeding in woman of childbearing potential

  10. Women of childbearing potential or male subjects must use a medically acceptable form of contraception as 2 barrier methods (e.g., combination of condom, diaphragm, or intrauterine device), hormonal contraception (estrogen or progesterone agents) or 1 barrier method in combination with spermicide. Birth control is required 1 month prior to screening, for the duration of their study participation, and for 1 month after the end of the study; female partners of male subjects must adhere to the same birth control methods.

  11. Provision of a signed and dated written Informed Consent Form (ICF) prior to any study specific procedures

  12. Subject is willing to comply with protocol-required visit schedule and visit requirements

  13. No more than 60 days have elapsed between completion of the prior line of chemotherapy or CCRT and enrollment

  14. Subject has not received other chemotherapy since first-line treatment

Exclusion Criteria:

  1. Have prior chemotherapy regimen other than first line gemcitabine and cisplatin-based therapy for unresectable metastatic or locally advanced BTC Note: prior fluoropyrimidine base (including capecitabine, carmofur (HCFU), doxifluridine, fluorouracil (5-FU), and tegafur) chemotherapy (including fluoropyrimidine monotherapy or combination therapy) are allowed as postsurgical adjuvant therapy.
  2. Diagnosis of active malignancy other than BTC within the past 2 years, except nonmelanoma skin carcinoma and carcinoma-in-situ of uterine cervix treated with curative intent
  3. Prior discontinuation of gemcitabine because of pulmonary or hepatic toxicity or hemolytic uremic syndrome (HUS) or hypersensitivity, allergic reaction, or intolerance
  4. Known or suspected hypersensitivity to capecitabine, tegafur, gimeracil, oteracil potassium, oxaliplatin or other platinum compounds, leucovorin products, folic acid or folinic acid, 5-fluorouracil or their excipients.
  5. Prior discontinuation of fluoropyrimidine because of any unexpected or severe reaction.
  6. Treatment with brivudine, sorivudine, or its chemically-related analogs ≤ 28 days prior to the date of enrollment.
  7. Under flucytosine treatment.
  8. Residual toxicity from prior chemotherapy or CCRT that is Grade ≥2 (residual Grade 2 neuropathy and alopecia are permitted)
  9. Any GI disorder which would significantly impede absorption of an oral agent
  10. Known brain or leptomeningeal metastases
  11. Major surgery or definitive ablation-intent (excluding palliative radiotherapy for bone metastasis) radiation therapy within the past 28 days
  12. Any active disease or condition that would not permit compliance with the protocol
  13. Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, congestive heart failure, or New York Heart Association [NYHA] Grade 2 or greater), or uncontrolled serious cardiac arrhythmia
  14. Have documented cerebrovascular disease. Subjects with the disease may be excluded, but if the investigator assesses that they are asymptomatic or well controlled could be enrolled.
  15. Have a seizure disorder not controlled on medication (based on decision of Investigator)
  16. Received an investigational agent within 28 days of enrollment
  17. Have an uncontrolled active viral, bacterial, or systemic fungal infection
  18. Known human immunodeficiency virus (HIV) infection
  19. Have HBsAg (hepatitis B surface antigen) positive with HBV-DNA ≥2000 copies/ml and/or anti-HCV antibody (HCV) positive with HCV-RNA positive.
  20. Received yellow fever vaccine or other live attenuated vaccine(s) within the 4 weeks prior to screening
  21. History of drug or alcohol abuse within last year
  22. Have any other serious medical condition that, in the Investigator's medical opinion, would preclude safe participation in, and compliance with, a clinical trial

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Phase IIa:Dose-Finding Stage

Level -5: 20 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).

Level -4: 40 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).

Level -3: 60 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).

Level -2: 80 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).

Level -1 (starting dose): 100 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).

Level 1: 100 mg D07001-softgel capsules plus 800 mg/m^2 Xeloda (or 30/40/50 mg TS-1).

Level 2: 100 mg D07001-softgel capsules plus 1000 mg/m^2 Xeloda (or 40/50/60 mg TS-1).

D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).

Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)

他の名前:
  • 治療群
アクティブコンパレータ:Phase IIb/III: Dose Expansion Stage

ASC+ D07001-softgel capsules plus Xeloda (or TS-1)

ASC+mFOLFOX (5-FU+Oxalipatin+folinic acid)

D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).

Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)

他の名前:
  • 治療群

intravenous infusion on Day 1 for 14-day cycle

他の名前:
  • 対照群

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of adverse events (AEs)/ serious adverse event (SAEs)
時間枠:From date of informed consent to 30-day follow-up visit for each subject

AEs will be assessed via the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03

From date of informed consent to 30-day follow-up visit for each subject
To assess disease control rate (DCR)
時間枠:From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months

To assess DCR, the percentage of treatment patients who achieved CR, PR, or SD.

From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Phase IIa and IIb: Pharmacokinetics (PK) of gemcitabine (dFdC), difluorodeoxyuridine (dFdU), capecitabine, 5-FU, Tegafur, Gimeracil, and Oteracil potassium
時間枠:Cycle 1 Days 1, 8, and 12 (each cycle is 21 days)

PK parameters (Peak Plasma Concentration (Cmax)) of gemcitabine and Xeloda or TS-1 will be evaluated

Cycle 1 Days 1, 8, and 12 (each cycle is 21 days)
Quality of life (QOL) will be assessed using the EORTC questionnaires
時間枠:Cycle 1 Days 1, and date of withdraw the study (assessed up to 24 months) for each subject (each cycle is 21 days)

To access healthrelated quality of life of cancer patients participating in clinical trial.

Cycle 1 Days 1, and date of withdraw the study (assessed up to 24 months) for each subject (each cycle is 21 days)
To assess Progression-free survival (PFS)
時間枠:From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months

To assess PFS, the time from treatment assignment/randomization until objective tumor progression or death

From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months
To assess Objective response rate (ORR)
時間枠:From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months

To assess ORR, the proportion of treated patients who achieved a BOR of CR or PR.

From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months
To assess overall survival (OS)
時間枠:The survival follow-ups will follow every 6 weeks from date of discontinued study drug for up to 24 months till the death of the subject or closure of the study.

To assess OS, the time from treatment assignment/randomization until death from any case

The survival follow-ups will follow every 6 weeks from date of discontinued study drug for up to 24 months till the death of the subject or closure of the study.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Li-Tzong Chen, Ph.D、National Institute of Cancer Research

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年3月29日

一次修了 (実際)

2025年7月31日

研究の完了 (実際)

2025年7月31日

試験登録日

最初に提出

2021年9月7日

QC基準を満たした最初の提出物

2021年9月23日

最初の投稿 (実際)

2021年10月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する